摘要
目的观察托伐普坦治疗心力衰竭合并肾功能不全的临床疗效及安全性。方法选取绵阳市中心医院心血管内科2017年1月~2019年1月收治的心力衰竭合并肾功能不全的110例患者,随机分为对照组和托伐普坦组,各55例。对照组给予常规对症治疗,托伐普坦组在对照组基础之上加用托伐普坦,比较两组治疗后1周和1个月的临床疗效及不良反应发生情况。结果托伐普坦组治疗后1周和1个月的总有效率、24 h尿量、血清钠、6 min步行距离均高于对照组,差异有统计学意义(P<0.05);托伐普坦组治疗后1周和1个月的proBNP水平、体重均低于对照组,差异有统计学意义(P<0.05);托伐普坦组治疗后1月的血肌酐、不良反应、再住院率和心衰纠正时间均低于对照组,差异有统计学意义(P<0.05)。结论托伐普坦能明显改善心力衰竭合并肾功能不全患者的临床症状、缩短心衰纠正时间、延缓肾功能恶化,同时不良反应发生率低。
Objective To observe the clinical efficacy and safety of tolvaptan in the treatment of heart failure with renal insufficiency.Methods A total of 110 patients with heart failure and renal insufficiency who were admitted to the Department of Cardiovascular Medicine of Mianyang Central Hospital from January 2017 to January 2019 were selected and randomly divided into control group and tolvaptan group,with 55 cases in each group.The control group was given conventional symptomatic treatment,and the tolvaptan group was given tolvaptan on the basis of the control group.The clinical efficacy and adverse reactions of the two groups were compared one week and one month after treatment.Results The total effective rate,24-hour urine output,serum sodium,and 6-min walking distance in the tolvaptan group at 1 week and 1 month after treatment were higher than those in the control group,the difference was statistically significant(P<0.05);tolvaptan the proBNP level and body weight of the tan group were lower than those of the control group one week and one month after treatment,the difference was statistically significant(P<0.05);the blood creatinine,adverse reactions,and rehospitalization rate of the tolvaptan group one month after treatment time to correct heart failure was lower than that of the control group,the difference was statistically significant(P<0.05).Conclusion Tolvaptan can significantly improve the clinical symptoms of patients with heart failure and renal insufficiency,shorten the correction time of heart failure,delay the deterioration of renal function,and reduce the incidence of adverse reactions.
作者
叶廷巧
赵亮
庾辉
龚倩
郑曦
YE Ting-qiao;ZHAO Liang;YU Hui;GONG Qian;ZHENG Xi(Department of Cardiovascular Medicine,Mianyang Central Hospital,Mianyang 621000,Sichuan,China;Department of Cardiovascular Medicine,Nanchuan District People's Hospital,Chongqing 408400,China)
出处
《医学信息》
2020年第15期69-72,共4页
Journal of Medical Information
